| Description | Soraprazan is a reversible, and fast-acting gastric H+/K+ ATPase inhibitor. |
| In vitro | Soraprazan is a potent gastric H,K-ATPase inhibitor(IC50 :0.1 μM) when measured in ion-leaky vesicles in the presence of 1 mM potassium. Soraprazan also effectively inhibits dibutyryl cAMP-stimulated [14C]AP accumulation in isolated gastric glands(IC50 of 0.19 μM )(0.09-0.40 μM geometric mean from n=6 with 95% confidence limits). In ion-leaky vesicles, soraprazan is a potent k-competitive the H,K-ATPase inhibitor(Ki of 6.4 nM). Soraprazan binds to the H,K-ATPase in ion-leaky vesicles with a Kd of 26.4 nM and a Bmax of 2.89 nmol/mg. |
| Synonyms | BYK61359 |
| molecular weight | 367.44 |
| Molecular formula | C21H25N3O3 |
| CAS | 261944-46-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 150 mg/mL (408.23 mM) |
| References | 1. Simon WA, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. |